Australia - engelsk - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - bicisate dihydrochloride, quantity: 0.9 mg - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; monobasic sodium phosphate; water for injections - [99mtc]-bicisate scintigraphy is indicated in the evaluation and localisation of regional perfusion abnormalities in adult patients with the central nervous system disorders of stroke and dementia.

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lantheus eu ltd. - bicisate dihydrochloride 0,9 mg - kit for radiopharmaceutical preparation - bicisate dihydrochloride 0.9 mg - technetium (99mtc) bicisate

USA - engelsk - NLM (National Library of Medicine)

lantheus medical imaging, inc. - bicisate dihydrochloride (unii: b005p07v07) (bicisate - unii:3jxf0z0xoi) - bicisate dihydrochloride 0.9 mg - neurolite single photon emission computerized tomography (spect) is indicated as an adjunct to conventional ct or mri imaging in the localization of stroke in patients in whom stroke has already been diagnosed. neurolite is not indicated for assessment of functional viability of brain tissue. also, neurolite is not indicated for distinguishing between stroke and other brain lesions. none known.

Israel - hebraisk - Ministry of Health

isorad ltd - technetium (99mtc) bicisate dihydrochloride 0.9 mg/vial - powder for solution for injection - technetium (99mtc) bicisate - evaluation of regional cerebral perfusion abnormalities in adult patients with central nervous system disorders.

Israel - engelsk - Ministry of Health

isorad ltd - technetium (99mtc) bicisate dihydrochloride 0.9 mg/vial - powder for solution for injection - technetium (99mtc) bicisate - evaluation of regional cerebral perfusion abnormalities in adult patients with central nervous system disorders.

Singapore - engelsk - HSA (Health Sciences Authority)

qt instruments (s) pte ltd - bicisate dihydrochloride (ecd.2hcl) (in vial a- ligand)) - injection, powder, for solution - 0.9 mg/vial - bicisate dihydrochloride (ecd.2hcl) (in vial a- ligand)) 0.9 mg/vial

Belgia - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lantheus eu - bicisate dihydrochloride - kit für ein radioaktives arzneimittel - bicisate dihydrochloride 0.9 mg - technetium (99mtc) bicisate

Taiwan - kinesisk - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

臺灣新吉美碩股份有限公司 台北市大安區復興南路一段237號11樓 (21241693) - bicisate dihydrochloride (ecd 2hcl) - 凍晶注射劑 - bicisate dihydrochloride (ecd 2hcl) (9200090510) mg - technetium (99mtc) bicisate - 評估患有中樞神經系統病變之成人患者局部腦血流灌注狀況。

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lantheus eu ltd. - dichlorhydrate de bicisate 0,9 mg - trousse pour préparation radiopharmaceutique - dichlorhydrate de bicisate 0.9 mg - technetium (99mtc) bicisate

USA - engelsk - NLM (National Library of Medicine)

jubilant draximage (usa) inc. - technetium tc-99m sestamibi (unii: 971z4w1s09) (technetium tc-99m sestamibi - unii:971z4w1s09) - tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate 1 mg in 1 ml - myocardial imaging: kit for the preparation of technetium tc 99m sestamibi injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. technetium tc 99m sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). it is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. breast imaging: kit for the preparation of technetium tc 99m sestamibi injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. kit f